Jb Michel is a data science expert who has made significant contributions to the fields of systems biology, culturomics, and drug discovery. With over a decade of experience across various industries, Jb has built a reputation for creating insightful solutions using big data.

Jb's academic journey began at Ecole Polytechnique, where he studied Mathematics and Computer Science. He later pursued a Masters in Applied Mathematics and a PhD in Systems Biology at Harvard University. During his time at Harvard, Jb co-discovered a new paradigm for identifying drug targets in rare and incurable bacterial diseases.

Jb's work has been recognized by many prestigious institutions, including Forbes' "30 under 30", TED, and Claremont Graduate University, which awarded him an honorary PhD in Science.

Before joining BenevolentAI, Jb spent some excellent years at Palantir Technologies, where he helped grow their data analysis business by developing new technologies for various industries. He went on to co-found two startups, Quantified Labs and Art Is Priceless, before joining BenevolentAI.

At BenevolentAI, Jb built and led the team responsible for creating their target identification product, which suggests gene targets and compounds for given diseases, mechanisms, and patient groups using AI and data science.

Jb's various experiences across academia and industry have given him a unique perspective on data science, drug discovery, and technology. Today, he continues to innovate and solve complex problems at BenevolentAI, working closely with their partners to develop the next generation of AI solutions.